一品红:创新药氘泊替诺雷(AR882)治疗痛风石最新临床成果在ACR 2025发布

GateNews

金十数据10月29日讯,一品红宣布,公司在研痛风创新药氘泊替诺雷(AR882)治疗痛风石最新临床成果在ACR2025(美国风湿病学会年会)发布。临床结论显示,对初治及难治性痛风石患者,氘泊替诺雷单药治疗或与别嘌醇联合治疗,可以有效降低sUA、降低尿酸盐晶体负荷且靶痛风石完全溶解率高。氘泊替诺雷单药或联合治疗,可为现有治疗方案疗效不佳的慢性痛风石患者提供一种更加有效的治疗选择。

Disclaimer: The information on this page may come from third parties and does not represent the views or opinions of Gate. The content displayed on this page is for reference only and does not constitute any financial, investment, or legal advice. Gate does not guarantee the accuracy or completeness of the information and shall not be liable for any losses arising from the use of this information. Virtual asset investments carry high risks and are subject to significant price volatility. You may lose all of your invested principal. Please fully understand the relevant risks and make prudent decisions based on your own financial situation and risk tolerance. For details, please refer to Disclaimer.
Commento
0/400
Nessun commento